The US Patent and Trademark Office (USPTO) will today (Aug. 21) issue new rules intended to streamline the patenting process. But the change will also make it more costly and time consuming for universities and biotech companies to secure rights to their life sciences discoveries, patent experts say.
The new rules, to be published in today's Federal Register, will restrict the number of times patent applications can be re-evaluated and will also limit the number of claims contained in any one application. Inventors will be limited to two new continuing applications, through which they can add additional claims to the same patent, and only one request for a continued examination, which an inventor can file after the patent office has rejected his or her patent application. The rules, which will take effect Nov. 1, 2007, also restrict to 25 the number of claims in any single patent submission.
In its original proposal, published Jan. 3, 2006, the USPTO sought one continuing examination application and 10 representative claims, but modified these in response to "extensive" public comments, the agency noted yesterday.
Currently, applicants can file an unlimited number of continuation requests accompanied by new arguments and evidence to support their claims. That strategy is frequently employed by universities and biotech companies when the full scope of their discoveries cannot be immediately established or when researchers seek to extend patent coverage from one or two new molecules to an entire class of compounds.
Under the new rules, applicants must demonstrate why an additional continuation is necessary and provide supplementary information to support additional claims.
"It's going to have a big effect on biotechs, universities, and nonprofits because it limits their ability to fight with the PTO," said Ronald Eisenstein, a partner in the biotech and intellectual property group at the law firm Nixon Peabody in Boston. "If all that the patent examiner has to say is no, it's going to get much harder to negotiate, and will lead to applicants having to file costly appeals," he told The Scientist.
Still unknown are USPTO's criteria for approving requests for continuations and additional claims. "There will be some cases, probably ones with significant claims, that we would like to continue to pursue that may end up being impacted," said Jon Soderstrom, managing director of the Office of Cooperative Research at Yale University. "The question is, what are the grounds of actually receiving an extension? That's the critical issue - the criteria that they will enforce," he told The Scientist.
For several years the patent office has been struggling to reduce its backlog of cases - currently around 750,000. Nearly one-third of the 355,000 new patent applications received in fiscal 2004 involved resubmissions of previous applications - a situation patent officials say impedes productivity and delays the issuing of new, well-qualified patents.
"Some accommodation has to be made for the bad situation due to the backlog," said Carl E. Gulbrandsen, managing director of the Wisconsin Alumni Research Foundation, the tech transfer office of the University of Wisconsin-Madison. "I would rather give a little bit on the front end [in terms of restricting the number of continuations and claims] and hope that we get more patents on the back end," he told The Scientist.
"These rules better focus examination and will bring closure to the examination process more quickly, while ensuring quality and maintaining the right balance between flexibility for applicants and the rights of the public," USPTO Director Jon Dudas said in a statement yesterday.
Ted Agres
mail@the-scientist.com
Links within this article
"Changes To Practice for Continued Examination Filings, Patent Applications Containing Patentably Indistinct Claims, and Examination of Claims in Patent Applications; Final Rule," Federal Register, Aug. 21, 2007
http://a257.g.akamaitech.net/7/257/2422
T. Agres, "USPTO proposes controversial patent filing changes"
http://www.thescientist.com/article/display/23177
Ronald Eisenstein
http://www.nixonpeabody.com/attorneys_detail1.asp?ID=58
Jon Soderstrom
http://www.yale.edu/ocr/about/who/soderstrom.html
Carl E. Gulbrandsen
http://www.warf.org/contact/staff.jsp?staff_id=52
E. Silverman, "The trouble with tech transfer," The Scientist, January 1, 2006.
http://www.the-scientist.com/article/display/39379
USPTO announcement
http://www.uspto.gov/main/homepagenews/bak2007aug20.htm

[Comment posted 2007-09-03 09:51:09]
Of "getting more patents," note text appearing in the San Diego Business Journal on 3 September 2007:
--Currently, the number of patent applications pending has reached 750,000, according to Rankin Byrne [USPTO spokesperson]. She says the agency has had to limit the number of patents it allows each year. --
In passing, note Gulbrandsen currently sits on an advisory committee to the federal Patent and Trademark Office [USPTO]. See for example
LINK
[see also various posts on IPBiz.blogspot about the continuing application issue.]
[Comment posted 2007-08-27 06:44:45]
[Comment posted 2007-08-24 09:47:25]
The only way the issue of back log can be addressed successfully is to announce a moratorium on new applications for a period of six months to a year- new applications could be registered but will not be responded to by USPTO for a period announced in the moratorium. This will give sufficient room to deal with the back log and start with implementation of new rules created to prevent such a back-log in the future.
[Comment posted 2007-08-23 08:22:46]
Data of the USPTO for FY 2005 showed that there were 63,000 continuing applications, which included 44,500 cons/cips and 18,500 divisionals. Of these, 11,800 were second, or subsequent, applications. Separately, there were 52,000 RCEs, of which 10,000 were second, or subsequent. Thus, 21,800 applications of 384,228, were second or subsequent, which is 5.7%. As for FY2004, RCEs were the single most abundant ?continuing? form, 52,000 of 384,228 [13.5%]. All ?continuing? forms combined constituted 115,000 of 384,228 [30%].
One notes that the "target" of the initial rules change (second or more filings of continuing applications) comprised only 5.7% of all filings. The modified rules will impact still fewer filings. Separately, the major continuing application form is the RCE. RCE's are filed when the examiner and applicant can't reach agreement over the claims as presented. That is where the major problem is.
There has been a lot of misinformation about the underlying reasons for the rule changes (see 88 JPTOS 743 for discussion of faulty reporting by Science). Separately, it is quite possible that there will be a legal challenge to the new rules.
(for example, LINK